Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 02, 2019 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing...
December 10, 2018 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer

CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring...
November 15, 2018 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies

Event to be webcast live at 12 pm ET CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer...
November 06, 2018 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

ATLAS™-identified “inhibitory” neoantigens promote tumor growth in mouse model ATLAS platform continues to differentiate versus in silico methods for true neoantigen identification CAMBRIDGE,...
November 01, 2018 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Reports Third Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patientsPresenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., Nov. 01,...
October 25, 2018 08:05 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Third Quarter 2018 Financial Results Conference Call & Webcast on November 1, 2018 at 9:00 a.m. ET

CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will...
October 09, 2018 08:35 ET | Source: Genocea Biosciences, Inc.

Genocea Announces Upcoming Presentations at SITC 2018

Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea...
October 01, 2018 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Strengthens Leadership Team: Thomas Davis, M.D. Appointed Chief Medical Officer; Derek Meisner, J.D. Joins as General Counsel

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two...
September 24, 2018 08:02 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at Two October Investor Conferences

CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...
August 29, 2018 08:05 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at Two September Investor Conferences

CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...